PLGA基于纳米粒子的抗TLR2 scFv基因传递用于治疗阿尔茨海默氏症
Subeen Lee1, Jaesung Lee1, Jaekyung Jeon2
1Interdisciplinary Program in Neuroscience, College of Natural Science, Seoul National University, Seoul 08826, Korea.
Experimental neurobiology
|January 19, 2026
概括
使用纳米颗粒的新型基因疗法在阿尔茨海默病模型中有效降低了神经炎症. 单剂量通过准微质托尔类受体2 (TLR2) 信号传递,改善了记忆力和减少了粉样蛋白斑块.
科学领域:
- 神经科学是一个神经科学.
- 生物技术是生物技术.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 的特点是持续的微质神经炎症.
- 目前的AD疗法对大脑的暴露和耐用性有限,需要新的长效治疗方法.
研究的目的:
- 开发一种非病毒基因疗法,以持续抑制大脑中微质Toll-like受体2 (TLR2) 信号传递.
- 在阿尔茨海默病小鼠模型中评估这种治疗的疗效.
主要方法:
- 开发了装载着编码反TLR2单链变量片段 (scFv33) 的等离子体的聚乳糖合糖酸 (PLGA) 纳米粒子 (NP).
- 在小鼠中输送scFv33装载的PLGANP.
- 使用新型物体识别 (NOR) 试验评估认知功能.
- 粉样β (Aβ) 斑块和微质形态的组织学分析.
- 使用初级神经元-微细胞共同培养的体外研究.
主要成果:
- 在单次给药后,PLGA NPs表现出微质偏差吸收和大脑范围的转基因表达.
- 在5xFAD小鼠中,scFv33 NPs显著改善了识别记忆,表现优于长期重组蛋白治疗.
- 组织学揭示了海马Aβ斑块的减少以及向分支的转移,少激活的微质形态.
- 在体外,scFv33治疗减少了微质缩,恢复了神经元复杂性,并增强了Aβ细胞化.
结论:
- 通过PLGA平台对抗TLR2 scFv的持续局部表达重新校准了微质状态.
- 这种单剂量基因疗法优先限制早期斑块积累,并在阿尔茨海默病模型中提供认知益处.
- 开发的基于PLGA的基因疗法代表了治疗阿尔茨海默病的临床可转化方法.
相关概念视频
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...